Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease
To access this article, please choose from the options below
The authors are indebted to all the patients and their legal guardians who participated in this study.
The authors disclose the following: Dr Richard Cross is an employee of iQur Limited; Prof. William M. Rosenberg is founder and holds stock in iQur Limited. M.P. and W.M.R. contributed equally to this paper.
PII: S0016-5085(08)01678-8
doi:10.1053/j.gastro.2008.09.013
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.

